Navigation Links
Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
Date:1/8/2013

Boston, MA (PRWEB) January 08, 2013

The U.S. Food and Drug Administration (FDA) approved JUXTAPID™ (lomitapide), a new, first-in-class treatment option for clinical management of patients with homozygous familial hypercholesterolemia (HoFH) on December 28, 2012. The FDA decision prompted the Cardiometabolic Health Congress (CMHC) expert faculty to examine the implications this new treatment option may have on physician practice and patient care.

HoFH, an inherited genetic disorder caused by a mutation to the LDL receptor, is associated with early onset of atherosclerosis and premature cardiac death. Patients with HoFH tend to respond poorly to statin therapy because of low LDL receptor activity. For patients with HoFH who do not respond to statin therapy, LDL apheresis is indicated. This approach is expensive, invasive, and not universally available or effective alone – many patients do not achieve target LDL-C levels and as many as 30 percent of pediatric patients receiving long-term LDL apheresis progress to atherosclerotic disease of the coronary arteries and/or aorta.

Daniel Rader, MD, Cooper-McClure Professor of Medicine and Pharmacology and chief of the Division of Translational Medicine and Human Genetics in the Department of Medicine, the Perelman School of Medicine at the University of Pennsylvania, stated, “The magnitude of LDL-C and apoB reduction seen with lomitapide in patients with HoFH is substantially greater than that achieved with any other pharmacologic therapies in this disease and is expected to change the course of the disease and delay the onset and progression of atherosclerotic cardiovascular disease.”

For patients with HoFH, heart and vascular disease often develop in childhood, and the average age of death is approximately 30 years. For this reason, Robert H. Eckel, MD, co-chair of the CMHC and professor of medicine at the University of Colorado Anschutz Medical Campus remarked, “The FDA decision to approve lomitapide provides a new option for patients with HoFH, who so often develop extensive atherosclerotic cardiovascular disease as children, and remain inadequately treated.” Christie Ballantyne, MD, co-chair of the CMHC, chief, Section of Cardiovascular Research and Cardiology at Baylor College of Medicine and director of the Center for Cardiovascular Disease Prevention at Methodist DeBakey Heart and Vascular Center echoed a similar sentiment: “I am excited that we will have a new treatment option available for patients with HoFH.”

Sergio Fazio, MD, PhD, the Cornelius Vanderbilt Professor of Medicine and Pathology at Vanderbilt University School of Medicine in Nashville, Tenn., and chief of the Section of Cardiovascular Disease Prevention, cited the significance of the lomitapide approval: “This novel therapy is at the other end of the spectrum of cholesterol-lowering therapies – not a drug for everyone, like the statins, but an extreme intervention for extreme situations. Its mechanism of action is based on the inhibition of MTP, an intracellular protein that moves the lipid droplet to the forming lipoprotein in the liver and intestine. By targeting lipoprotein assembly, lomitapide has the power to reduce cholesterol irrespective of the type of mutation causing FH, since its effect is not based on up-regulation of the LDL receptor.”

Convening Oct. 2–5, 2013, in Boston, the CMHC is co-chaired by George L. Bakris, MD; Christie M. Ballantyne, MD; Robert H. Eckel, MD; and Jay S. Skyler, MD, MACP. The CMHC provides the most advanced-level cardiometabolic education encompassing a multitude of risk factors, including cardiovascular disease, obesity, type 2 diabetes, dyslipidemia, atherosclerosis, hypertension, thrombosis, acute coronary syndrome, chronic kidney disease and related comorbidities.

For more information, contact Dina Kouveliotes at info(at)cardiometabolichealth(dot)org or 877-571-4700 or visit http://www.cardiometabolichealth.org.

Disclosures:

Dr. Christie Ballantyne – Consultant: Aegerion Pharmaceuticals

Dr. Sergio Fazio – Consultant: participated in an advisory meeting sponsored by Aegerion Pharmaceuticals

Dr. Daniel Rader – Ownership Interest/Shareholder: Aegerion Pharmaceuticals

Read the full story at http://www.prweb.com/releases/2013/1/prweb10293283.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Midwest Healthcare Startups Raise $996 Million in 2012
2. HealthEconomics.Com Appoints New Director of Information Technology and Operations
3. Join Cato BioVentures and Cancer Advances at Biotech Showcase 2013 & J.P. Morgan 31st Annual Healthcare Conference
4. BulletinHealthcare a TOP 10 “Most Innovative Company” of 2012 According to Pharma Marketing Publication PM360
5. First Maryland Hospital Offering 3D Mammograms? VA Maryland Health Care System
6. Opedix® Kinetic Health Gear Unveils New KNEE-Tec™ Knee Support Tights Shown to Reduce Quadriceps Muscle Fatigue and Knee Pain
7. The Medzilla Employment Report for December, 2012: Unemployment Drops to Lowest Rate in 4 Years; Experts Predict Unprecedented Growth in Healthcare IT
8. Life Solutions Advocates Announces New Partnerships in Health Promotion and Disease Prevention Initiative
9. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Feature Rising Trend in Pharma Price Cuts to Secure Reimbursement
10. Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference
11. Analysis of Venture Capital Investment Trends in the North American and European Healthcare Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... ... support for Connecticut's innovative, growing companies, today announced the launch of VentureClash ... technology (fintech) companies. , “VentureClash looks to attract the best early-stage ...
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, the ... technology, today announced that it has been named to The Silicon Review’s “20 Fastest ... and other markets, Cambridge Semantics serves the needs of end users facing some of ...
(Date:4/27/2016)... Columbia , April 27, 2016 ... "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... Anschluss an ihre Pressemitteilung vom 13. August 2015 ... hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten auf ... Kanadische Dollar zu bringen. Davon wurden 157.900.000 Einheiten ...
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, Inc., ... Advisory Board. Dr. Lamka will assist PathSensors in expanding the use of the ... deploys the CANARY® test platform for the detection of harmful pathogens, including a ...
Breaking Biology Technology:
(Date:3/17/2016)... 2016 ABI Research, the leader in ... biometrics market will reach more than $30 billion ... 2015. Consumer electronics, particularly smartphones, continue to boost ... to reach two billion shipments by 2021 at ... , Research Analyst at ABI Research. "Surveillance is ...
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... ) - --> - Renvoi : image ... --> --> ... biométriques, fournit de nouveaux lecteurs d,empreintes digitales pour ... de DERMALOG sera utilisé pour produire des cartes ...
(Date:3/10/2016)... 2016   Unisys Corporation (NYSE: UIS ) ... (CBP) is testing its biometric identity solution at the Otay ... to help identify certain non-U.S. citizens leaving the country. ... to help determine the efficiency and accuracy of using biometric ... will run until May 2016. --> the ...
Breaking Biology News(10 mins):